MedImmune Ventures
VC Fund
Gaithersburg, United States
MedImmune Ventures is a VC fund in Gaithersburg focused on Biotechnology and Health Care. MedImmune Ventures invests in early to late stage, public and private biotechnology companies.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries MedImmune Ventures invests in
BiotechnologyHealth CarePharmaceuticalMedicalTherapeutics
Stages MedImmune Ventures invests in
Series BSeries CSeries ASeries DFunding Round
Countries MedImmune Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ron Laufer
|
|||
Tyrell Rivers
|
|||
|
Franklin H. Top
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 19 (66%)
- Health Care 14 (48%)
- Pharmaceutical 8 (28%)
- Medical 6 (21%)
- Therapeutics 6 (21%)
Stage
- Series B 9 (31%)
- Series C 6 (21%)
- Series A 5 (17%)
- Series D 3 (10%)
- Funding Round 3 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ron Laufer
Senior Managing Director
|
Senior Managing Director | Total investments: 3 | Find email | |
|
Tyrell Rivers
Senior Associate
|
Senior Associate | Total investments: 1 | Find email | |
|
Franklin H. Top
Vice President
|
Vice President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $47M / Series C / May 11, 2016 | |
|
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $33M / Series B / Feb 05, 2015 | |
|
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | Series A / Oct 16, 2013 | |
Inotek Pharmaceuticals
|
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration(AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020. | $7M / Debt Financing / Sep 27, 2013 | |
|
Inotek Pharmaceuticals
|
Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration(AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020. | $21M / Sep 27, 2013 | |
AGTC
|
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused bybroken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. | $37.5M / Series B / Nov 19, 2012 | |
Ambit Biosciences
|
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $50M / Nov 06, 2012 | |
Cerapedics
|
Cerapedics is an orthobiologics company focused on developing its proprietary biomimetic small peptide molecule (P-15) for commercialization in spinal applications. The company was founded in 2001 and is headquartered in Westminster, Colorado. | $19M / Series C / Jul 23, 2012 | |
|
Ambit Biosciences
|
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $30M / Series D / Jun 10, 2011 | |
VentiRx Pharmaceuticals
|
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Itsproduct pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego. | $25M / Series A / Jan 13, 2010 | |
| See all 29 investments → | |||
Co-Investors
Care Capital
6 deals together
Forward Ventures
6 deals together
Rho Ventures
6 deals together
Intersouth Partners
4 deals together
Pitango VC
4 deals together
Gimv
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does MedImmune Ventures invest in?
MedImmune Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 29 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact MedImmune Ventures?
Public channels for MedImmune Ventures include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MedImmune Ventures?
The team at MedImmune Ventures includes Ron Laufer (Senior Managing Director), Tyrell Rivers (Senior Associate) and Franklin H. Top (Vice President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
